Medical device maker Poly Medicure aims to double its international revenue by fiscal year 2030 through new manufacturing plants and 50 new product launches. While focusing on emerging markets, the company expects domestic operations to grow faster than exports over the next four years.
Poly Medicure has announced a strategic plan to double its international business revenue by fiscal year 2030. According to company management, this goal is supported by the addition of two new manufacturing facilities and a pipeline of over 50 new products spanning critical care, cardiology, oncology, and vascular access.
In the previous fiscal year, the company reported international revenue of ₹1,280.2 crore, which accounted for approximately 68% of its total revenue of ₹1,875.3 crore. The company intends to shift its focus toward the Global South, including markets in Southeast Asia, Latin America, Africa, and the Middle East, to drive this expansion.
Domestic Growth Outlook and Manufacturing
While international expansion remains a core objective, the company expects its domestic business to become a primary driver of growth. Management anticipates domestic revenue will grow by 20% to 25% annually over the next four to five years, potentially outpacing the projected export growth rate of 15% to 20%. This domestic momentum is expected to be fueled by increased demand for renal care, cardiology, and critical care products. The company plans to leverage local manufacturing to reduce costs, which is intended to increase the adoption of single-use dialysis devices within India.
Strategic Context and Market Environment
Regarding the global shift in supply chains away from China, the company noted that India has yet to capture a significant share of this transition. While earlier phases of relocation primarily benefited manufacturing hubs in countries like Vietnam and Malaysia, the company believes that future phases—specifically those involving high-tech medical devices—could create more favorable conditions for Indian manufacturers seeking to supply European markets.
Investor Monitorables
For investors, the success of this strategy will depend on several factors, including the timely completion of the two new manufacturing facilities and the successful regulatory approval and commercial launch of the new product pipeline. Additionally, investors may track whether the company can maintain its domestic growth targets as planned and how effectively it navigates potential pricing pressure in emerging markets. Sustaining margins while scaling up these large capital-intensive projects remains a key area for monitoring in upcoming quarterly updates.